Neurotoxicity Research

, Volume 33, Issue 1, pp 24–32 | Cite as

Creating a Simian Model of Guam ALS/PDC Which Reflects Chamorro Lifetime BMAA Exposures

ORIGINAL ARTICLE

Abstract

The theory that β-N-methylamino-L-alanine (BMAA), a cyanobacterial toxin, contaminates traditional food supplies of the Chamorro people of Guam is supported by the recent finding that chronic dietary exposure to L-BMAA in vervets (Chlorocebus sabaeus) triggers the formation of neurofibrillary tangles (NFT) and β-amyloid plaques in the brain. In the first experiment, we found that all four vervets receiving a 210 mg/kg dose for 140 days developed NFT and sparse amyloid deposits. In the second experiment, all eight vervets receiving a 210 mg/kg dose for 140 days developed NFT and amyloid deposits, as well as all eight vervets that received only 21 mg/kg. Based on dietary surveys of the Chamorro people, we estimated lifetime chronic BMAA exposure at a high and a low level: 1) adult male Chamorros eating two flying foxes per month plus one 30 g serving of cycad flour per week; and 2) adult male Chamorros eating one 30 g serving of cycad flour per day combined with the consumption of eight flying foxes per month. The resultant cumulative lifetime Chamorro exposures ranged from 1 to 41 g/kg and are comparable to the total lifetime vervet exposures in our experiments of 2 and 22 g/kg, respectively. Furthermore, measured protein-bound BMAA concentrations of vervets fed L-BMAA powder are comparable to measured protein-bound BMAA concentrations in postmortem brain tissues of Chamorros who died with ALS/PDC.

Keywords

BMAA Neurofibrillary tangles β-Amyloid Guam ALS/PDC Nonhuman primate models Neurodegeneration Cyanobacteria 

Notes

Acknowledgements

We thank Roberta Palmour and the late Frank R. Ervin, Amy Beierschmitt, and the staff of the Behavioural Science Foundation in St. Kitts for overseeing the care and dosing of the vervets, Dr. Peter Wyatt of Queen Mary University of London and Dr. Peter Nunn of University of Portsmouth for technical advice, Ms. Jane Cox and Mr. James Powell for dose preparation, Mr. W. Broc Glover for sample preparation, Dr. James Metcalf for useful discussions, Dr. Robert Switzer and his team at NeuroScience Associates in Tennessee for helpful discussions at the initiation of the study and choice of antibodies, Dr. Deborah Mash, Dr. David Davis and the staff of the Miami Brain Endowment Bank at the Miller School of Medicine for collection and management of the biospecimens reported in this study, and Ms. Marilyn Asay for helping to prepare the manuscript.

Compliance with Ethical Standards

Funding

This study was supported by the Josephine P. and John J. Louis Foundation, the William Stamps Farish Fund, Douglas and Elizabeth Kinney, and Patrick and Heather Henry.

Ethics

This research was approved by the Institutional Animal Care and Use Committee (IACUC) of the Behavioural Sciences Foundation in St. Kitts. Animal care and health was monitored by an on-site DVM veterinarian.

Conflict of Interest

The Institute for Ethnomedicine has applied for a patent for screening potential drug candidates using BMAA-induced neurodegeneration (US 14/229,624).

References

  1. Al-Sammak MA, Hoagland KD, Cassada D, Snow DD (2014) Co-occurrence of the cyanotoxins BMAA, DABA and anatoxin-a in Nebraska reservoirs, fish, and aquatic plants. Toxins 6:488–508CrossRefPubMedPubMedCentralGoogle Scholar
  2. Anderson FH, Richardson EP, Okazaki H, Brody JA (1979) Neurofibrillary degeneration on Guam. Frequency in Chamorros with no known neurological disease. Brain 102:65–77CrossRefPubMedGoogle Scholar
  3. Andersson M, Karlsson O, Banack SA, Brandt I (2016) Transfer of developmental neurotoxin β-N-methylamino-L-alanine (BMAA) via milk to nursed offspring: studies by mass spectrometry and image analysis. Toxicol Lett 258:108–114CrossRefPubMedGoogle Scholar
  4. Arif M, Kazim SF, Grundke-Iqbal I, Garruto RM, Iqbal K (2014) Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam. Proc Natl Acad Sci USA 111:1144–1149Google Scholar
  5. Banack SA, Cox PA (2003) Biomagnification of cycad neurotoxins in flying foxes: implications for ALS-PDC in Guam. Neurology 61:387–389CrossRefPubMedGoogle Scholar
  6. Banack SA, Murch SJ, Cox PA (2006) Neurotoxic flying foxes as dietary items for the Chamorro people, Marianas Islands. J Ethnopharmacol 106:97–104CrossRefPubMedGoogle Scholar
  7. Banack SA, Cox PA, Murch SJ (2009) Flying fox consumption and human neurodegenerative disease in Guam. In: Fleming TH, Racey PA (eds) Island bats: ecology, evolution, and conservation. University of Chicago Press, ChicagoGoogle Scholar
  8. Borenstein AR, Mortimer JA, Schofield E, Wu Y, Salmon DP, Gamst A, Olichney J, Thal LJ, Silbert L, Kaye J, Craig UL (2007) Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology 68:1764–1771CrossRefPubMedGoogle Scholar
  9. Brand LE, Pablo J, Compton A, Hammerschlag N, Mash DC (2010) Cyanobacterial blooms and the occurrence of the neurotoxin, beta-N-methylamino-l-alanine (BMAA), in South Florida aquatic food webs. Harmful Algae 9:620–635CrossRefPubMedPubMedCentralGoogle Scholar
  10. Bräutigam A, Elmqvist T (1990) Conserving Pacific island flying foxes. Oryx 24:81–89CrossRefGoogle Scholar
  11. Brownson DM, Mabry TJ, Leslie SW (2002) The cycad neurotoxic amino acid, β-N-methylamino-l-alanine (BMAA), elevates intracellular calcium levels in dissociated rat brain cells. J Ethnopharmacol 82:159–167CrossRefPubMedGoogle Scholar
  12. Butterfield DA, Hall NC, Cross SJ (1993) Effects of beta-(N-methylamino)-L-alanine on cytoskeletal proteins of erythrocyte membranes. Chem Res Toxicol 6:417–420CrossRefPubMedGoogle Scholar
  13. Chen L (1981) Neurofibrillary change on Guam. Arch Neurol 38:16–18CrossRefPubMedGoogle Scholar
  14. Cheng R, Banack SA (2009) Previous studies underestimate BMAA concentrations in cycad flour. Amyotroph Lateral Scler 10:41–43CrossRefPubMedGoogle Scholar
  15. Chiu AS, Gehringer MM, Braidy N, Guillemin GJ, Welch JH, Neilan BA (2013) Gliotoxicity of the cyanotoxin, β-methyl-amino-L-alanine (BMAA). Sci Rep 3:1482CrossRefPubMedPubMedCentralGoogle Scholar
  16. Cox PA, Banack SA, Murch SJ (2003) Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci USA 100:13380–13383Google Scholar
  17. Cox PA, Banack SA, Murch SJ, Rasmussen U, Tien G, Bidigare RR, Metcalf JS, Morrison LF, Codd GA, Bergman B (2005) Diverse taxa of cyanobacteria produce β-N-methylamino–L-alanine, a neruotoxic amino acid. Proc Natl Acad Sci USA 102:5074–5078Google Scholar
  18. Cox PA, Banack SA, Murch SJ (2007) Cyanobacteria, cycads, and neurodegenerative disease among the Chamorro people of Guam. Mem N Y Bot Gard 97:253–285Google Scholar
  19. Cox PA, Davis DA, Mash DC, Metcalf JS, Banack SA (2016a) Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain. Proc R Soc B 283:20152397CrossRefPubMedPubMedCentralGoogle Scholar
  20. Cox PA, Davis DA, Mash DC, Metcalf JS, Banack SA (2016b) Do vervets and macaques respond differently to BMAA? Neurotoxicology 57:310–311Google Scholar
  21. Dunlop RA, Cox PA, Banack SA, Rodgers KJ (2013) The non-protein amino acid, BMAA, is misincorporated into human proteins in place of l-serine causing protein misfolding and aggregation. PLoS One 8:e75376CrossRefPubMedPubMedCentralGoogle Scholar
  22. Esterhuizen-Londt M, Wiegand C, Downing TG (2015) β-N-methylamino-l-alanine (BMAA) uptake by the animal model, Daphnia magna and subsequent oxidative stress. Toxicon 100:20–26CrossRefPubMedGoogle Scholar
  23. Frøyset AK, Khan EA, Fladmark KE (2016) Quantitative proteomics analysis of zebrafish exposed to sub-lethal dosages of β-methyl-amino-L-alanine (BMAA). Sci Rep 6:29631Google Scholar
  24. Galasko D, Salmon DP, Craig UK, Thal LJ, Schellenberg G, Wiederholt W (2002) Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997–2000. Neurology 58:90–97CrossRefPubMedGoogle Scholar
  25. Glover W, Baker TC, Murch SJ, Brown P (2015) Determination of β-N-methylamino-L-alanine, N-(2-aminoethyl) glycine, and 2, 4-diaminobutyric acid in food products containing cyanobacteria by ultra-performance liquid chromatography and tandem mass spectrometry: single-laboratory validation. J AOAC Int 98:1559–1565CrossRefPubMedGoogle Scholar
  26. Hirano A, Malamud N, Elizan TS, Kurland LT (1966) Amyotrophic lateral sclerosis and parkinsonism-dementia complex on Guam: further pathological studies. Arch Neurol 15:35–51CrossRefPubMedGoogle Scholar
  27. Hirano A, Malamud N, Kurland LT, Zimmerman HM (1968) A review of the pathologic findings in amyotrophic lateral sclerosis. In: Norris FH, Kurland LT (eds) Contemporary neurology symposium Vol II: motor neuron diseases: research on amyotrophic lateral sclerosis and related disorders. Grune and Stratton, New York, pp 51–60Google Scholar
  28. Jonasson S, Eriksson J, Berntzon L, Spáčil Z, Ilag LL, Ronnevi LO, Rasmussen U, Bergman B (2010) Transfer of a cyanobacterial neurotoxin within a temperate aquatic ecosystem suggests pathways for human exposure. Proc Natl Acad Sci USA 107:9252–9257Google Scholar
  29. Karamyan VT, Speth RC (2008) Animal models of BMAA neurotoxicity: a critical review. Life Sci 82:233–246CrossRefPubMedGoogle Scholar
  30. Karlsson O, Lindquist NG (2016) Melanin and neuromelanin binding of drugs and chemicals: toxicological implications. Arch Toxicol 90:1883–1891CrossRefPubMedGoogle Scholar
  31. Karlsson O, Berg C, Brittebo EB, Lindquist NG (2009a) Retention of the cyanobacterial neurotoxin β-N-methylamino-l-alanine in melanin and neuromelanin-containing cells–a possible link between Parkinson-dementia complex and pigmentary retinopathy. Pigment Cell Melanoma Res 22:120–130CrossRefPubMedGoogle Scholar
  32. Karlsson O, Roman E, Brittebo EB (2009b) Long-term cognitive impairments in adult rats treated neonatally with β-N-methylamino-L-alanine. Toxicol Sci 112:185–195CrossRefPubMedGoogle Scholar
  33. Karlsson O, Roman E, Berg AL, Brittebo EB (2011) Early hippocampal cell death, and late learning and memory deficits in rats exposed to the environmental toxin BMAA (β-N-methylamino-L-alanine) during the neonatal period. Behav Brain Res 219:310–320CrossRefPubMedGoogle Scholar
  34. Karlsson O, Berg AL, Lindström AK, Arnerup G, Roman E, Bergquist J, Hanrieder J, Lindquist NG, Brittebo E, Andersson M (2012) Neonatal exposure to the cyanobacterial toxin BMAA induces changes in protein expression, and neurodegeneration in adult hippocampus. Toxicol Sci 130(2):391–404Google Scholar
  35. Koenig JH, Goto JJ, Ikeda K (2015) Novel NMDA receptor-specific desensitization/inactivation produced by ingestion of the neurotoxins, β-N-methylamino-L-alanine (BMAA) or β-N-oxalylamino-L-alanine (BOAA/β-ODAP). Comp Biochem Physiol C Toxicol Pharmacol 167:43–50CrossRefPubMedGoogle Scholar
  36. Lavine L, Steele JC, Wolfe N, Calne DB, O'Brien PC, Williams DB, Kurland LT, Schoenberg BS (1991) Amyotrophic lateral sclerosis/parkinsonism-dementia complex in southern Guam: is it disappearing? Adv Neurol 56:271–285PubMedGoogle Scholar
  37. Li A, Song J, Hu Y, Deng L, Ding L, Li M (2016) New typical vector of neurotoxin β-N-methylamino-l-alanine (BMAA) in the marine benthic ecosystem. Mar Drugs 14:202CrossRefPubMedCentralGoogle Scholar
  38. Liu X, Rush T, Zapata J, Lobner D (2009) β-N-methylamino-l-alanine induces oxidative stress and glutamate release through action on system Xc−. Exp Neurol 217:429–433CrossRefPubMedGoogle Scholar
  39. Lobner D, Piana PMT, Salous AK, Peoples RW (2007) β-N-methylamino-L-alanine enhances neurotoxicity through multiple mechanisms. Neurobiol Dis 25:360–366CrossRefPubMedGoogle Scholar
  40. Main BJ, Dunlop RA, Rodgers KJ (2016) The use of l-serine to prevent β-methylamino-L-alanine (BMAA)-induced proteotoxic stress in vitro. Toxicon 31:7–12CrossRefGoogle Scholar
  41. Monson CS, Banack SA, Cox PA (2003) Conservation implications of Chamorro consumption of flying foxes as a possible cause of amyotrophic lateral sclerosis–parkinsonism dementia complex in Guam. Conserv Biol 17:678–686CrossRefGoogle Scholar
  42. de Munck E, Muñoz-Sáez E, Antonio MT, Pineda J, Herrera A, Miguel BG, Arahuetes RM (2013) Effect of β-N-methylamino-l-alanine on oxidative stress of liver and kidney in rat. Environ Toxicol Pharmacol 35:193–199CrossRefPubMedGoogle Scholar
  43. Muñoz-Saez E, de Munck E, Arahuetes RM, Solas MT, Martínez AM, Miguel BG (2013) β-N-methylamino-L-alanine induces changes in both GSK3 and TDP-43 in human neuroblastoma. J Toxicol Sci 38:425–430CrossRefPubMedGoogle Scholar
  44. Murch SJ, Cox PA, Banack SA (2004a) A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc Natl Acad Sci USA 101:12228–12231Google Scholar
  45. Murch SJ, Cox PA, Banack SA, Steele JC, Sacks OW (2004b) Occurrence of β-N-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand 110:267–269CrossRefPubMedGoogle Scholar
  46. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C et al. (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 5:362–381Google Scholar
  47. Ogden CL, Fryar CD, Carroll MD, Flegal KM (2004) Mean body weight, height, and body mass index, United States 1960–2002. Advance Data from Vital and Health Statistics; no 347. National Center for Health Statistics, HyattsvilleGoogle Scholar
  48. Perry TL, Hansen S, Kennedy J (1975) CSF amino acids and plasma-CSF amino acid ratios in adults. J Neurochem 24:587–589CrossRefPubMedGoogle Scholar
  49. Popova AA, Koksharova OA (2016) Neurotoxic non-proteinogenic amino acid β-N-methylamino-L-alanine and its role in biological systems. Biochem Mosc 81:794–805CrossRefGoogle Scholar
  50. Rao SD, Banack SA, Cox PA, Weiss JH (2006) BMAA selectively injures motor neurons via AMPA/kainate receptor activation. Exp Neurol 201:244–252CrossRefPubMedGoogle Scholar
  51. Reed D, Plato C, Elizan T, Kurland LT (1966) The amyotrophic lateral sclerosis/parkinsonism-dementia complex: a ten-year follow-up on Guam: part I. Epidemiologic studies. Am J Epidemiol 83:54–73CrossRefPubMedGoogle Scholar
  52. Reed D, Labarthe D, Chen KM, Stallones R (1987) A cohort study of amyotrophic lateral sclerosis and parkinsonism-dementia on Guam and Rota. Am J Epidemiol 125:92–100CrossRefPubMedGoogle Scholar
  53. Rush T, Liu X, Lobner D (2012) Synergistic toxicity of the environmental neurotoxins methylmercury and β-N-methylamino-L-alanine. Neuroreport 23:216–219CrossRefPubMedGoogle Scholar
  54. Sheeline L (1991) Cultural significance of Pacific fruit bats (Pteropus) to the Chamorro people of Guam. Conservation implications. Report. World Wildlife Fund and Traffic USA, Washington, D.C.Google Scholar
  55. Shen H, Kim K, Oh Y, Yoon KS, Baik HH, Kim SS, Ha J, Kang I, Choe W (2016) Neurotoxin β-N-methylamino-L-alanine induces endoplasmic reticulum stress-mediated neuronal apoptosis. Mol Med Rep 14:4873–4880CrossRefPubMedGoogle Scholar
  56. U.S. Fish and Wildlife Service (2005) Mariana flying fox. RIN 1018-AH55. Fed Regist 70:1190–1210Google Scholar
  57. Whiting MG (1963) Toxicity of cycads. Econ Bot 17:270–302CrossRefGoogle Scholar
  58. Xie X, Basile M, Mash DC (2013) Cerebral uptake and protein incorporation of cyanobacterial toxin β-N-methylamino-L-alanine. Neuroreport 24:779–784CrossRefPubMedGoogle Scholar
  59. Yin HZ, Yu S, Hsu C-I, Liu J, Acab A, Wu R, Tao A, Chiang BJ, Weiss JH (2014) Intrathecal infusion of BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord. Exper Neur 261:1–9CrossRefGoogle Scholar
  60. Zhang ZX, Anderson DW, Mantel N, Roman GC (1996) Motor-neuron disease in Guam: geographic and familial occurrence, 1956-85. Acta Neurol Scand 94:51–79CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017
Corrected publication September/2017

Authors and Affiliations

  1. 1.Brain Chemistry LabsInstitute for EthnomedicineJacksonUSA

Personalised recommendations